DarouPakhsh Holding Company (Public Company)

History

DarouPakhsh Holding Company (DPHC) was first established and registered in 1957 in Tehran as “DarouPakhsh Charity Institution”. Following the glorious 1979 Islamic Revolution, the former Ministry of Health assumed its ownership in 1980 with the approval of the Council of Islamic Revolution and was re-registered under the name of “DarouPakhsh Joint-Stock Company” in Tehran. DPHC was transferred to the Iranian Social Security Organization (SSO) in 1992 following an act by the Islamic Consultative Assembly. The company type was changed to public company pursuant to an act by the extraordinary general meeting in 1994 and was listed in the Tehran Stock Exchange (TSE) as the 140th company therein following it’s the approval of TSE Listing Board. DPHC operates as an investment company since 1997, following the approval of the extraordinary annual general meeting and simultaneously with the dissociation of the last manufacturing company (DarouPakhsh Pharmaceutical MFG Co.), and is currently a subsidiary of Tamin Pharmaceutical Investment Co. (TPICO).

Features

- Over 60 years of brilliant history and a reputable brand in the national pharmaceutical industry.
- An optimal combination of the pharmaceutical system value chain consisting of manufacturing, distribution, and trading companies
- Optimal, effective use of intragroup potentials, and maintenance and development of principal capacities and competence in order to gain sustainable competitive advantages, maintain the market, and identify emerging opportunities.
- Ranked 50 and 2 among the top 100 Iranian companies and in the pharmaceutical material and product category, respectively, next to TPICO based on the top Iranian companies ranking by the Industrial management Institute of Iran in 2016 (IMI-100 Ranking).
- Prioritization of sustainable growth and excellence in the group and earning multiple certificates in areas related to quality, strategic management, organizational excellence, human recourses, etc.
- Benefitting from about 4,440 competent, expert, and committed manpower.

Message from the CEO

In the Name of God

Health has always constituted one of the major and most sensitive concerns related to the human quality of life throughout the world. Accordingly, the health system has always been among the major strategic sectors of the industry. As one of the fundamental pillars of the health system, the pharmaceutical system has always been recognized as an important criterion for determining a country’s extent of development, leading the world countries to improve their international status through the development of their capacities in this area. After the glorious Islamic Revolution, the Iranian pharmaceutical industry has been consistently and rapidly moving toward growth and excellence resulting in self-sufficiency in this industry’s value chain in line with the requirements of a resistive economy and the significant active presence by the national pharmaceutical companies in advanced technology areas such as biotechnology and nanotechnology. This is achieved by producing a wide range of raw materials and pharmaceutical products which, in addition to meeting the domestic market needs, prepares the ground for domestic pharmaceuticals to enter the global market. This can, undoubtedly, improve the status of the domestic pharmaceutical industry and health system throughout the region and world.
As one of the largest national pharmaceutical groups with over 60 years of brilliant experience covering a wide range of the pharmaceutical system value chain including production, distribution, and trade, DarouPakhsh Co. constantly strives to achieve sustainable value creation, secure the interests of its stakeholders, and improve the public health level in line with its organizational motto “DarouPakhsh: the symbol of health and value creation” through the dynamic leadership of the group companies in the form of the strategic-oriented organizational excellence road map. To this end, the strategic orientations of DarouPakhsh are focused on sustainable value creating, improving stakeholders’ satisfaction, optimizing and improving the value chain efficiency, enhancing organizational procedure excellence, and creating synergy among organizational capitals. We pursue these goals by implementing modern management systems, state-of-the-art knowledge and technology, and specialized, committed human capital and hope to attain an innovative, knowledge-based, synergetic, superior, committed to stakeholders, and value-creator company through the insight, intelligence, diligence, and ceaseless endeavors of group companies’ managers and staff, in line with the goals of a resistive economy, maintain our privileged status in the national health system, and play a favorable and constructive role in the fulfillment of the national sustainable development. We look forward to a bright future together.
Farshad Malekvandfard- CEO

Mission Statement & Vision Statement


Mission Statement

With over 60 years of brilliant history in the national pharmaceutical industry and as one of the largest pharmaceutical groups, DPHC covers a wide range of the pharmaceutical system value chain including manufacturing, distribution, and trade and strives toward upholding its core values, puts effort into pursuing of sustainable value creation and supplying the interests of all its stakeholders, as well as improving the health level of the society through dynamic management of the affiliated companies and using the new management systems, up-to-date technologies and specialized human capital.

Vision Statement

DPHC’s vision is in line with the 2025 National Vision Plan of the Islamic Republic of Iran;
Value-creating, committed to stakeholders, synergist and transcendental, innovator and knowledge-based with a unique status in the national health system and serving a constructive role in the national sustainable development.

Core Values Statement


A win-win viewpoint and commitment to meet the stakeholders’ expectations
Mutual trust, teamwork spirit, and participative leadership
Observing ethical principles in individual and organizational interactions
Deontologism (duty ethics) and efficient/effective use of resources
Development and empowerment of human capital
Reputability with a prestigious brand
Transparency and accountability in performance reporting

Board of Directors

Managing Director and Member of the Board: Farshad Malekvand Fard
The Bachelor of Accountancy from Shahid Beheshti University, Tehran, Iran
Chairman of the Board: Dr. Mohammadreza Shanehsaz Porshoshtari
Ph.D. in Pharmacy from Medical Sciences University, Isfahan, Iran
Vice Chairman of the Board: Mohammad Ali Vatani
Bachelor of Banking
Member of the Board: Ali Asghari
The Master of Accountancy from Science and Research University, Tehran, Iran
Member of the Board: Dr. Seyed Farshad Fatemi Ardestani
PhD in Economics from University College London (UCL), London, UK

Stockholder composition



Stockholder composition

Achieved by DarouPakhsh Co. (Public Company)

Rank 50 among the Top 100 Iranian Companies and Rank 2 in the Pharmaceutical Material and Product Category in the 2016 Top Iranian Companies Ranking

Since 1998, the Industrial Management Institute (IMI) of Iran ranks the top Iranian companies each year. Inspired by the company’s mission, this ranking provides transparent and useful information and statistics on the country’s business establishments and the economic business environment, helping business establishment managers, policy makers, and researchers achieve a more accurate understanding of the scale, and financial and economic structures of large national industries and economic establishments.
>> read more

















Rank 50 among the Top 100 Iranian Companies and Rank 2 in the Pharmaceutical Material and Product Category in the 2016 Top Iranian Companies Ranking

Since 1998, the Industrial Management Institute (IMI) of Iran ranks the top Iranian companies each year. Inspired by the company’s mission, this ranking provides transparent and useful information and statistics on the country’s business establishments and the economic business environment, helping business establishment managers, policy makers, and researchers achieve a more accurate understanding of the scale, and financial and economic structures of large national industries and economic establishments.
>> read more

Introduction of DarouPakhsh Group Affiliated Companies

  • DarouPakhsh Pharmaceutical MFG Co. (Public Company)

  • Exir Pharmaceutical Company (public company)

  • Aburaihan Pharmaceutical Co. (public company)

  • Zahravi Pharmaceutical Co. (public company)

  • Razak Labs. Co. (public company)

  • Zagros Pharmed Pars Co. (public company)

  • DarouPakhsh Distribution Co. (public company)

  • Exir Pharmaceutical Distribution Co. (privately held)

  • DarouPakhsh Veterinary Pharmaceutical Distribution Co. (privately held)

  • DarouPakhsh Trade Promotion Co. (privately held)

  • Biodarou Co. (privately held)

Knowledge base

World Health Day’s 2017 theme is: ‘Depression: Let’s Talk’

Depression is the leading cause of ill health and disability worldwide. According to the latest estimates from WHO, more than 300 million people are now living with depression, an increase of more than 18% between 2005 and 2015. Lack of support for people with mental disorders, coupled with a fear of stigma, prevent many from accessing the treatment they need to live healthy, productive lives.
The new estimates have been released in the lead-up to World Health Day on 7 April, the high point in WHO’s year-long campaign “Depression: let’s talk”. The overall goal of the campaign is that more people with depression, everywhere in the world, both seek and get help. Said WHO Director-General, Dr Margaret Chan: “These new figures are a wake-up call for all countries to re-think their approaches to mental health and to treat it with the urgency that it deserves.”
One of the first steps is to address issues around prejudice and discrimination. “The continuing stigma associated with mental illness was the reason why we decided to name our campaign Depression: let’s talk,” said Dr Shekhar Saxena, Director of the Department of Mental Health and Substance Abuse at WHO. “For someone living with depression, talking to a person they trust is often the first step towards treatment and recovery.”

Read more

Strategic Planning and Studies: the 4th Evaluation and Ranking Ceremony of SSIC Subsidiaries

The in-person evaluation of all TPICO’s companies, as the selected companies in the first phase of the 4th SSIC subsidiary ranking ceremony lasted from January 13- 20, 2018. The project’s mission is to assess the realization of the Social Security Organization’s macro strategies for improving investment returns, explaining and translating the Social Security Investment Company’s policies for its subsidiaries, and their continuous monitoring.

Read more


Strategic Planning and Studies: the 4th Evaluation and Ranking Ceremony of SSIC Subsidiaries

The in-person evaluation of all TPICO’s companies, as the selected companies in the first phase of the 4th SSIC subsidiary ranking ceremony lasted from January 13- 20, 2018. The project’s mission is to assess the realization of the Social Security Organization’s macro strategies for improving investment returns, explaining and translating the Social Security Investment Company’s policies for its subsidiaries, and their continuous monitoring.

Read more


Contact us

Address : 2nd Floor - No.81- West Nahid St - Opposite the Mellat Park - Valiasr Street - Tehran - I.R.IRAN
Postal code : 1966913481

Phone : (021) 22650125 - 7     -     Fax : (021) 22650130

   Google map
DarouPakhsh